Wave Life Sciences Ltd. — Director's Dealing 2019

Dec 6, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2019-12-03

Reporting Person: Vargeese Chandra (Senior VP, Drug Discovery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-03	Ordinary Shares	M	6000	$2.48	Acquired	46245	Direct
2019-12-03	Ordinary Shares	S	6000	$35.00	Disposed	40245	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-03	Share Option (right to buy)	$2.48	M	6000	Disposed	2025-03-10	Ordinary Shares (6000)	Direct

Footnotes

F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019.

F2: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.